Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
Want to see GB:SCLP full AI Analyst Report?
SCLP Stock Chart & Stats
9.75 p
0.40 p(4.06%)
At close: 4:00 PM EST
9.75 p
0.40 p(4.06%)
Day’s Range― - ―
52-Week Range7.86 p - 29.50 p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.20M
Market Cap
£259.45M
Enterprise Value282.62M
Total Cash (Recent Filing)£8.57M
Total Debt (Recent Filing)£16.18M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£1.20M
Bulls Say, Bears Say
Bulls Say
FDA IND Clearance & Accelerated-approval PathwayFDA IND clearance and acceptance of a surrogate primary endpoint materially de-risks development strategy: it validates the clinical design, manufacturing and endpoints, enables an accelerated regulatory path and increases partner and investor confidence in eventual commercialization prospects.
Strong Phase II Efficacy Signal (iSCIB1+)A robust PFS signal from Phase II provides durable clinical validation of the modality and a justified registrational hypothesis: this strengthens the likelihood of positive Phase III readouts, enhances bargaining power with partners, and supports long-term commercial potential if confirmed.
Pipeline Breadth And Partnered Commercialization UpsideA diversified pipeline plus meaningful partnered upside (Genmab milestones) and progressing partnered antibodies create multiple, structural value pathways beyond the lead asset; this reduces single-program risk and offers realistic non-dilutive funding or milestone liquidity if clinical progress continues.
Bears Say
Negative Shareholder Equity And Elevated DebtNegative equity and material debt relative to modest assets weaken solvency optics and reduce financial flexibility. Over the medium term this limits the company's ability to fund expensive development internally and increases reliance on dilutive financing or partner deals.
Persistent Cash Burn And Near-term Funding NeedOngoing negative operating and free cash flow plus a runway into H2 2026 create a structural funding imperative: the company must secure partner payments, milestones or financing, which risks dilution, deal pressure and could constrain execution of the planned Phase III without external support.
Long, Blinded Phase III Timeline To Registrational ReadoutA multi-year blinded Phase III with a H2 2029 readout extends uncertainty and execution risk: investors and partners face a long wait for confirmatory evidence, increasing funding needs, potential competitive changes, and reliance on interim non-dilutive milestones to sustain operations.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 7.86 p and its highest was 29.50 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £259.45M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 156 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,037,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.25%
12-Months-Change
Fundamentals
Return on Equity
90.29%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---